Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference crossover study of subcutaneous fixed-dose pertuzumab + trastuzumab in HER2-positive early breast cancer
2018-002153-30Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Patient preference for subcutaneous administration. Started Sep 2018; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-002153-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002153-30.